Pharmacogenomics From Basic Research to Clinical Implementation
This Special Issue focuses on the current state of pharmacogenomics (PGx) and the extensive translational process, including the identification of functionally important PGx variation; the characterization of PGx haplotypes and metabolizer statuses, their clinical interpretation, clinical decision s...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_81067 | ||
| 005 | 20220506 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20220506s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a books978-3-0365-2834-2 | ||
| 020 | |a 9783036528359 | ||
| 020 | |a 9783036528342 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.3390/books978-3-0365-2834-2 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 072 | 7 | |a MMG |2 bicssc | |
| 100 | 1 | |a Scheinfeldt, Laura B. |4 edt | |
| 700 | 1 | |a Scheinfeldt, Laura B. |4 oth | |
| 245 | 1 | 0 | |a Pharmacogenomics |b From Basic Research to Clinical Implementation |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (162 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a This Special Issue focuses on the current state of pharmacogenomics (PGx) and the extensive translational process, including the identification of functionally important PGx variation; the characterization of PGx haplotypes and metabolizer statuses, their clinical interpretation, clinical decision support, and the incorporation of PGx into clinical care. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 650 | 7 | |a Pharmacology |2 bicssc | |
| 653 | |a pharmacogenomics | ||
| 653 | |a return of results | ||
| 653 | |a genetic counseling | ||
| 653 | |a qualitative | ||
| 653 | |a pharmacogenetics | ||
| 653 | |a implementation | ||
| 653 | |a pharmacogenetics service | ||
| 653 | |a screening | ||
| 653 | |a pre-emptive | ||
| 653 | |a personalized medicine | ||
| 653 | |a precision medicine | ||
| 653 | |a community pharmacy | ||
| 653 | |a pharmacogenomic testing | ||
| 653 | |a genetic privacy | ||
| 653 | |a pharmaco-economics | ||
| 653 | |a polymorphisms | ||
| 653 | |a pharmacogenes | ||
| 653 | |a pharmacogenomic | ||
| 653 | |a machine learning | ||
| 653 | |a adaptation | ||
| 653 | |a human evolution | ||
| 653 | |a US Food and Drug Administration | ||
| 653 | |a clinical actionability | ||
| 653 | |a clinical translation | ||
| 653 | |a chronic kidney disease | ||
| 653 | |a CYP3A5 | ||
| 653 | |a polymorphism | ||
| 653 | |a progression | ||
| 653 | |a pharmacogenomics (PGx) | ||
| 653 | |a pediatrics | ||
| 653 | |a best practice alerts (BPAs) | ||
| 653 | |a electronic health records (EHR) | ||
| 653 | |a genomic indicators | ||
| 653 | |a clinical decision support (CDS) | ||
| 653 | |a phenotype | ||
| 653 | |a genotype | ||
| 653 | |a polypharmacy | ||
| 653 | |a chronic disease | ||
| 653 | |a medication management | ||
| 653 | |a electronic medical record | ||
| 653 | |a artificial intelligence | ||
| 653 | |a n/a | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5095 |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/81067 |7 0 |z DOAB: description of the publication |